Insulet Corporation
Insulet Corporation Reports Strong Third Quarter 2024 Financial Results and Raises Guidance
Summary
Insulet Corporation announced its third quarter 2024 financial results on November 7, 2024, reporting a 26% year-over-year revenue increase. The company raised its full-year revenue and margin guidance, anticipating revenue growth of 20-21% and a gross margin of approximately 69%. Adjusted net income was $64.2 million, or $0.90 per diluted share, and adjusted EBITDA was $126.1 million. The press release and condensed consolidated financial statements are furnished as Exhibit 99.1.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement